Neutropenia, a common complication in patients administered myelosuppressive chemotherapy for nonmyeloid malignancies, is often treated with granulocyte colony-stimulating factors (G-CSFs). A budget impact study comparing home-administration of tbo-filgrastim, filgrastim-sndz, and filgrastim suggests that increasing tbo-filgrastim and filgrastim-sndz utilization for patients who self-administer the drugs may offer a more affordable option for US payers.
Tbo-filgrastim (Granix) and filgrastim-sndz (Zarxio) are, respectively, a follow-on biologic and a biosimilar version of the reference G-CSF filgrastim (Neupogen), with comparable efficacy and safety. Researchers Holly Trautman, PharmD, MS, of Aventine Consulting, Marblehead, MA, and colleagues created a budget impact model to estimate increasing utilization of home (patient)-administered tbo-filgrastim and filgrastim-sndz in patients with nonmyeloid malignancies treated with myelosuppressive chemotherapy from a US payer perspective. They estimated the changes in drug costs associated with projected increases in market share of tbo-filgrastim from 5% to 10% and filgrastim-sndz from 10% to 12%, for a 1-million-member health plan. The overall budget impact was calculated over a 1-year period, along with the difference in per-member, per-year (PMPY) cost between current and future scenarios. One-way sensitivity analyses were also conducted.
It was assumed that 20% of patients receiving short-acting G-CSFs were self-administrating the medications at home. All products were decided upon through pharmacy benefits (Tier 3 formulary status; patient co-pay of $54/prescription). The model assumed syringe replacement rates of 1% for tbo-filgrastim and 5% for filgrastim and filgrastim-sndz because of differences in stability.
The effective annual plan per-patient drug cost totaled between $17,249 and $27,657, depending on dose and presentation, for tbo-filgrastim; between $17,043 and $27,332 for filgrastim-sndz; and between $18,034 and $32,212 for filgrastim. The estimated overall annual plan cost associated with short-acting G-CSFs was $55,920,046 (PMPY, $55.92) in the current scenario and $55,346,277 (PMPY, $55.34) in the future scenario. Estimated cost savings totaled $573,769 (PMPY, $0.58). The authors said the model was most sensitive to changes in the overall proportion of patients self-administering G-CSFs at home and to the wholesale acquisition cost for filgrastim.
Based on their analysis, the authors concluded that the effective annual plan per-patient drug cost for tbo-filgrastim and filgrastim-sndz was 14% to 15% lower than for filgrastim. “Estimated annual US health plan cost savings were in excess of $0.5 million overall, or $0.50 PMPY following small shifts in market shares,” they noted.
The authors presented their findings at the annual meeting of the Academy of Managed Care Pharmacy in Denver, Colorado, March 27-30, 2017.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.